Cargando…

Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report

Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Daoan, Tang, Shuxian, Li, Dong, Zhao, Weiqing, Wei, Wei, Fang, Cheng, Ji, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374065/
https://www.ncbi.nlm.nih.gov/pubmed/35946524
http://dx.doi.org/10.1097/CAD.0000000000001368
_version_ 1784767715440852992
author Cheng, Daoan
Tang, Shuxian
Li, Dong
Zhao, Weiqing
Wei, Wei
Fang, Cheng
Ji, Mei
author_facet Cheng, Daoan
Tang, Shuxian
Li, Dong
Zhao, Weiqing
Wei, Wei
Fang, Cheng
Ji, Mei
author_sort Cheng, Daoan
collection PubMed
description Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient after osimertinib resistance who was successfully treated by high-dose furmonertinib (AST2818) at 160 mg. The patient initially received the GCP regimen for 11 months and displayed partial response. The patient received osimertinib 80 mg at the time of progression with a stable clinical and radiological response lasting only 7 months. Subsequently, she was commenced on furmonertinib 160 mg once daily. After 2 weeks of furmonertinib, the patient’s tumor was markedly smaller on a follow-up chest CT scan, and her respiratory symptoms also improved. What shocked us was that after a month’s re-examination of the cranial MRI, the intracranial lesions wholly disappeared. This report provides a case of the successful rescue of osimertinib-resistant NSCLC patients by oral administration of high-dose furmonertinib 160 mg daily, providing a new treatment option for osimertinib-resistant patients.
format Online
Article
Text
id pubmed-9374065
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93740652022-08-19 Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report Cheng, Daoan Tang, Shuxian Li, Dong Zhao, Weiqing Wei, Wei Fang, Cheng Ji, Mei Anticancer Drugs Case Reports Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient after osimertinib resistance who was successfully treated by high-dose furmonertinib (AST2818) at 160 mg. The patient initially received the GCP regimen for 11 months and displayed partial response. The patient received osimertinib 80 mg at the time of progression with a stable clinical and radiological response lasting only 7 months. Subsequently, she was commenced on furmonertinib 160 mg once daily. After 2 weeks of furmonertinib, the patient’s tumor was markedly smaller on a follow-up chest CT scan, and her respiratory symptoms also improved. What shocked us was that after a month’s re-examination of the cranial MRI, the intracranial lesions wholly disappeared. This report provides a case of the successful rescue of osimertinib-resistant NSCLC patients by oral administration of high-dose furmonertinib 160 mg daily, providing a new treatment option for osimertinib-resistant patients. Lippincott Williams & Wilkins 2022-08-10 2022-09 /pmc/articles/PMC9374065/ /pubmed/35946524 http://dx.doi.org/10.1097/CAD.0000000000001368 Text en Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Reports
Cheng, Daoan
Tang, Shuxian
Li, Dong
Zhao, Weiqing
Wei, Wei
Fang, Cheng
Ji, Mei
Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
title Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
title_full Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
title_fullStr Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
title_full_unstemmed Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
title_short Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
title_sort successful salvage therapy using high-dose furmonertinib (ast2818) for non–small-cell lung cancer after osimertinib resistance: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374065/
https://www.ncbi.nlm.nih.gov/pubmed/35946524
http://dx.doi.org/10.1097/CAD.0000000000001368
work_keys_str_mv AT chengdaoan successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport
AT tangshuxian successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport
AT lidong successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport
AT zhaoweiqing successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport
AT weiwei successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport
AT fangcheng successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport
AT jimei successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport